Tag: IND application

Cabaletta Bio’s IND application for CABA-201 to treat systemic lupus erythematosus has been approved by the US FDA.

The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy that contains the 4-1BB protein, according to Cabaletta Bio, Inc., a clinical-stage biotechnology company focused…

To treat patients with solid tumours, Sensei Biotherapeutics has submitted an IND application to the US FDA for a phase 1/2 trial of SNS-101.

An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial in patients with solid tumours, according to Sensei Biotherapeutics, Inc.,…

Back to top

This will close in 0 seconds

Registration Form


This will close in 0 seconds